An optimized intranasal LNP formulation for potent immune responses of mRNA-based RSV vaccines
Nanoscale · 2025 · 17 (42) · 24541-24553
DOI: 10.1039/d5nr01452b ↗Kurz gefasst
Fachartikel in der Zeitschrift Nanoscale, 2025. Verfasst von Yan Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Liverna Therapeutics Inc., Zhuhai, 519000, China. pengyucai@live-rna.com. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Vaccines, RNA, Messenger, Respiratory Syncytial Virus Infections, Respiratory Syncytial Viruses. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Abstract (Originalsprache)
The first intranasally delivered RSV mRNA-LNP vaccine induces robust mucosal IgA responses in both upper and lower respiratory tracts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Liverna Therapeutics Inc., Zhuhai, 519000, China. pengyucai@live-rna.com.
- School of Life Sciences, Zhuhai College of Science and Technology, Zhuhai 519041, China.
Zitieren
APA
Li, Y., Long, H., Wang, C., Weng, J., Kuang, Z., & Peng, Y. (2025). An optimized intranasal LNP formulation for potent immune responses of mRNA-based RSV vaccines. Nanoscale, 17(42), 24541-24553. https://doi.org/10.1039/d5nr01452b
Vancouver
Li Y, Long H, Wang C, Weng J, Kuang Z, Peng Y. An optimized intranasal LNP formulation for potent immune responses of mRNA-based RSV vaccines. Nanoscale. 2025;17(42):24541-24553. doi:10.1039/d5nr01452b
BibTeX
@article{Li2025,
author = {Li, Yan and Long, Haiyan and Wang, Chunxia and Weng, Jiayi and Kuang, Ziyun and Peng, Yucai},
title = {An optimized intranasal LNP formulation for potent immune responses of mRNA-based RSV vaccines},
journal = {Nanoscale},
year = {2025},
volume = {17},
number = {42},
pages = {24541--24553},
doi = {10.1039/d5nr01452b}
}
EUVIMED